We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ariad Pharmaceuticals, Inc. | NASDAQ:ARIA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 23.99 | 23.80 | 22.88 | 0 | 01:00:00 |
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that clinical data on Iclusig® (ponatinib) will be presented at the 20th conference of the European Hematology Association (EHA) being held in Vienna, Austria, June 11 to 14, 2015.
The schedule and meeting location for the sessions, together with the abstract information, are listed below:
Title:Ponatinib Efficacy and Safety in Heavily Pretreated Leukemia Patients: 3-Year Results of the PACE Trial
Abstract No: P234 Presenter: Jorge Cortes, M.D., (The University of Texas MD Anderson Cancer Center, Houston, US) Poster Session: Chronic myeloid leukemia – Clinical 1 Date & Time: Friday, 12 June, 2015, 17:15 – 18:45 (CEST) Location: Poster Area, Hall C Title:
Long-Term Follow-up of Ponatinib Efficacy and Safety in Patients (Pts) with the T315I Mutation in the Phase 1 and Phase 2 (PACE) Trials
Abstract No: P236 Presenter: Michele Baccarani, M.D., (University of Bologna, Italy) Poster Session: Chronic myeloid leukemia - Clinical 1 Date & Time: Friday, 12 June, 2015, 17:15 – 18:45 (CEST) Location: Poster Area, Hall C Title:Minimum Follow-up of 4 Years for Ongoing Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in a Phase 1 Trial of Ponatinib
Abstract No: P237 Presenter: Moshe Talpaz, M.D., (University of Michigan Medical Center, Ann Arbor, US) Poster Session: Chronic myeloid leukemia – Clinical 1 Date & Time: Friday, 12 June, 2015, 17:15 – 18:45 (CEST) Location: Poster Area, Hall C Title:Responses at Early Landmark Time Points are Associated with Outcomes in Heavily Pretreated CP-CML Patients (Pts) Treated with Ponatinib
Abstract No: P235 Presenter: Martin C. Müller, M.D. (Medical Clinic, University Hospital Mannheim, Mannheim, Germany) Poster Session: Chronic myeloid leukemia – Clinical 1 Date & Time: Friday, 12 June, 2015, 17:15 – 18:45 (CEST) Location: Poster Area, Hall C Title:A Model-Based Assessment of the Benefits and Risks of Ponatinib Versus Bosutinib in Third-Line Treatment of Chronic Myeloid Leukemia (CP-CML)
Abstract No: P424 Presenter: Shannon Cartier, M.D., (Optum, Burlington, Canada) Oral Session: Quality of life, palliative care, ethics and health economics Date & Time: Friday, 12 June, 2015, 17:15 – 18:45 (CEST) Location: Poster Area, Hall CAbout Iclusig® (ponatinib) tablets
Iclusig is approved in the U.S., EU, Switzerland, Australia, Israel and Canada. Iclusig is a kinase inhibitor indicated in the EU for adult patients with:
About ARIAD
ARIAD Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts and Lausanne, Switzerland, is an integrated global oncology company focused on transforming the lives of cancer patients with breakthrough medicines. ARIAD is working on new medicines to advance the treatment of various forms of chronic and acute leukemia, lung cancer and other difficult-to-treat cancers. ARIAD utilizes computational and structural approaches to design small-molecule drugs that overcome resistance to existing cancer medicines. For additional information, visit http://www.ariad.com or follow ARIAD on Twitter (@ARIADPharm).
Iclusig® is a registered trademark of ARIAD Pharmaceuticals, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150522005100/en/
ARIAD PharmaceuticalsFor InvestorsKendra Adams, 617-503-7028Kendra.adams@ariad.comorFor U.S. MediaLiza Heapes, 617-621-2315Liza.heapes@ariad.comorFor EU MediaGemma White, +44 (0)20 337 25 221gwhite@biosector2.co.uk
1 Year Ariad Chart |
1 Month Ariad Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions